Table 2.
Treatment-related grade 3 or 4 adverse events in ≥ 5% of Patients
Preferred Term n (%) |
Initial Dose 85mg (n=28) |
Initial Dose 110 mg (n=23) |
Total (n=51) |
---|---|---|---|
Thrombocytopenia | 7 (25.0) | 4 (17.4) | 11 (21.6) |
Fatigue | 3 (10.7) | 5 (21.7) | 8 (15.7) |
Neutropenia | 3 (10.7) | 4 (17.4) | 7 (13.7) |
Pneumonia | 2 (7.1) | 4 (17.4) | 6 (11.8) |
Anemia | 4 (14.3) | 1 (4.3) | 5 (9.8) |
Pericardial effusion | 1 (3.6) | 2 (8.7) | 3 (5.9) |
Abnormal liver function test | 1 (3.6) | 2 (8.7) | 3 (5.9) |